Odalasvir - Misplaced Pages

Chemical compound Pharmaceutical compound

Odalasvir
Legal status

Legal status	US: Investigational New Drug
Identifiers
IUPAC name Dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane- 1,4-diylbis{1H-benzimidazole-5,2-diyl })biscarbamate
CAS Number	1415119-52-6
PubChem CID	71474517
ChemSpider	34500837
UNII	OVR52K7BDW
CompTox Dashboard (EPA)	DTXSID401032258
Chemical and physical data
Formula	C₆₀H₇₂N₈O₆
Molar mass	1001.286 g·mol
3D model (JSmol)	Interactive image
SMILES CC(C)(C(=O)N12CCCC2C1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)1C2CCCC2N1C(=O)(C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1 Key:LSYBRGMTRKJATA-IVEWBXRVSA-N

Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by Achillion Pharmaceuticals.

References

"International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73" (PDF). who.int. World Health Organization. p. 38. Retrieved 5 December 2015.
"Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. Retrieved 15 November 2015.
"Odalasvir". ChemIDplus.
Walker T (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas". Managed Healthcare Executive: 47. Retrieved March 12, 2016.
Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O (March 2014). "Hepatitis C virus NS5A inhibitors and drug resistance mutations". World Journal of Gastroenterology. 20 (11): 2902–12. doi:10.3748/wjg.v20.i11.2902. PMC 3961994. PMID 24659881.
"ACH-3102 resources". Achillion Pharmaceuticals. Winter 2011. Retrieved 1 May 2012.
"Achillion gets FDA incentives for hepatitis C drug". Associated Press. 15 May 2012. Archived from the original on May 22, 2012.
Levin J (18–22 April 2012). Preclinical characteristics of ACH-3102. 47th Annual Meeting. Barcelona, Spain: European Association for the Study of the Liver.

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir Danoprevir Faldaprevir Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir Telaprevir Vaniprevir Vedroprevir Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir Elbasvir Ledipasvir Odalasvir Ombitasvir Pibrentasvir Ravidasvir Ruzasvir Samatasvir Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir Bemnifosbuvir Dasabuvir Deleobuvir Filibuvir GS-6620 IDX-184 Setrobuvir Sofosbuvir Tegobuvir TMC-647055 Radalbuvir Uprifosbuvir
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a Peginterferon alfa-2b
3CL protease inhibitors (–trelvir)	Ensitrelvir Ibuzatrelvir Lufotrelvir Nirmatrelvir (+ritonavir) Rupintrivir Simnotrelvir (+ritonavir)
RNA pol inhibitors	CMX521 Deuremidevir Favipiravir Galidesivir GS-441524 Remdesivir MK-608 Mericitabine Molnupiravir NITD008 Ribavirin Taribavirin Triazavirin Valopicitabine
Multiple/Unknown/Other	EICAR Merimepodib Moroxydine Presatovir

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.